<DOC>
	<DOCNO>NCT01371305</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability subcutaneously ( SC ) administer multiple , escalate dos BG00011 ( humanize monoclonal antibody direct alpha v beta 6 ( αvβ6 ) integrin , formerly know STX-100 ) participant IPF . The Secondary objective estimate pharmacokinetic ( PK ) parameters 1st dose last dose multiple , escalate dos BG00011 participant IPF , assess immunogenicity BG00011 participant IPF , assess effect BG00011 biomarkers isolate bronchoalveolar lavage ( BAL ) peripheral blood participant IPF .</brief_summary>
	<brief_title>STX-100 Patients With Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description>This study previously post Stromedix , Inc . In April , 2014 , sponsorship trial transfer Biogen . The study drug name change STX-100 BG00011 study number change STX-003 203PF201 , align sponsor convention .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Key 1 . Clinical feature consistent IPF prior screen ( base American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) /Japanese Respiratory Society ( JRS ) /Latin American Thoracic Association ( ALAT ) consensus criterion diagnosis IPF ) . 2 . Forced ( expiratory ) Vital Capacity ( FVC ) ≥ 50 % predict value . 3 . DLco ( correct hemoglobin ) ≥ 30 % predict value . 4 . Oxygen saturation &gt; 90 % rest pulse oximetry breathe ambient air receive ≤2 L/minute supplemental oxygen . 5 . Residual volume ≤ 120 % predict value . 6 . Ratio Forced Expiratory Volume 1 second ( FEV1 ) FVC ≥ 0.65 use bronchodilator . 7 . Other known cause interstitial lung disease exclude ( e.g. , drug toxicity , environmental exposure , connective tissue disease ) . 8 . High Resolution Computed Tomography ( HRCT ) image fulfills criteria 'Usual Interstitial Pneumonia ( UIP ) pattern ' . 9 . If HRCT image fulfill criterion 'UIP pattern ' surgical lung biopsy necessary diagnosis IPF ( lung biopsy perform prior screen acceptable ) . If lung biopsy perform , must fulfill histopathological criterion either 'UIP pattern ' 'probable UIP pattern ' appropriate HRCT correlate . 10 . Adequate bone marrow liver function . 11 . Patient life expectancy least 12 month . Key 1 . Findings diagnostic condition UIP surgical lung biopsy ( perform either screen ) , HRCT imaging , transbronchial lung biopsy , bronchoalveolar lavage ( BAL ) . 2 . Serious local infection systemic infection within 3 month prior screen . 3 . Treatment another investigational drug , investigational device , approve therapy investigational use within 4 week initial screen . 4 . Currently receive high dose corticosteroid , cytotoxic therapy ( e.g. , chlorambucil , azathioprine , cyclophosphamide , methotrexate ) , nintedanib ( Ofev® ) , vasodilator therapy pulmonary hypertension ( e.g. , bosentan ) , unapproved and/or investigational therapy IPF administration therapeutic within 5 halflives agent prior initial screen study . 5 . Endstage fibrotic disease require organ transplantation within 6 month NOTE : Other protocol define Inclusion/Exclusion Criteria may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>